Ovarian Cancer Coverage from Every Angle
Advertisement
Advertisement

Ursula A. Matulonis, MD, and Jacob Korach, MD, on AML Risk in Ovarian Cancer: Results From the SOLO2 Trial

Posted: Monday, June 11, 2018

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Jacob Korach, MD, of Sheba Medical Center, Tel Aviv University, discuss study findings on the incidence of myelodysplastic syndrome and acute myeloid leukemia in patients with platinum-sensitive relapsed ovarian cancer receiving maintenance olaparib.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.